Abiraterone, a drug that can extend the lives of men with incurable prostate cancer, has been approved for use in Scotland, the last part of the UK to make it available on the NHS.
The disease, which kills 10,000 men a year, is the second most common cause of cancer deaths in UK men.
The Scottish Medicines Consortium (SMC) had previously rejected a submission to allow the drug to be used in Scotland as they believed the cost of £3,000 a month did not justify the health benefits. However after reversing it's initial decision the SMC has decided to restrict the drug to patients who have only received one chemotherapy regime.
The verdict has been welcomed by cancer charities such as Prostate Cancer UK whose chief executive, Owen Sharp, was pleased at the decision. He said "Today brings a victory for both decency and common sense. Abiraterone has now been approved for use on the NHS UK-wide and I thank and congratulate everyone who backed us and helped us achieve this result." Also Dr Harpal Kumar, chief executive at Cancer Research UK, commented that although Abiraterone is not a cure, it can provide men with crucial extra months at the end of their lives.
Now that doctors across the whole of the UK are able to prescribe the drug to men with prostate cancer, it can give hope to sufferers of the disease by giving them the time to do what they want before they die.
Jack

No comments:
Post a Comment